SG11202102105VA - Methods and compositions for treating aging-associated impairments using ccr3-inhibitors - Google Patents

Methods and compositions for treating aging-associated impairments using ccr3-inhibitors

Info

Publication number
SG11202102105VA
SG11202102105VA SG11202102105VA SG11202102105VA SG11202102105VA SG 11202102105V A SG11202102105V A SG 11202102105VA SG 11202102105V A SG11202102105V A SG 11202102105VA SG 11202102105V A SG11202102105V A SG 11202102105VA SG 11202102105V A SG11202102105V A SG 11202102105VA
Authority
SG
Singapore
Prior art keywords
ccr3
inhibitors
compositions
methods
treating aging
Prior art date
Application number
SG11202102105VA
Inventor
Steven P Braithwaite
S Sakura Minami
Karoly Nikolich
Arnaud E J Teichert
Sanket V Rege
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkahest Inc filed Critical Alkahest Inc
Publication of SG11202102105VA publication Critical patent/SG11202102105VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
SG11202102105VA 2018-09-26 2019-09-25 Methods and compositions for treating aging-associated impairments using ccr3-inhibitors SG11202102105VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862737017P 2018-09-26 2018-09-26
PCT/US2019/052995 WO2020069008A1 (en) 2018-09-26 2019-09-25 Methods and compositions for treating aging-associated impairments using ccr3-inhibitors

Publications (1)

Publication Number Publication Date
SG11202102105VA true SG11202102105VA (en) 2021-04-29

Family

ID=69953286

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102105VA SG11202102105VA (en) 2018-09-26 2019-09-25 Methods and compositions for treating aging-associated impairments using ccr3-inhibitors

Country Status (16)

Country Link
EP (1) EP3856195A4 (en)
JP (1) JP2022502441A (en)
KR (1) KR20210065950A (en)
CN (1) CN112789044A (en)
AU (1) AU2019346456A1 (en)
BR (1) BR112021004938A2 (en)
CA (1) CA3111433A1 (en)
CL (1) CL2021000724A1 (en)
CO (1) CO2021003713A2 (en)
EA (1) EA202190463A1 (en)
IL (1) IL281578A (en)
MA (1) MA53743A (en)
MX (1) MX2021002967A (en)
SG (1) SG11202102105VA (en)
TW (1) TW202027752A (en)
WO (1) WO2020069008A1 (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200538098A (en) * 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
EP1996551A2 (en) * 2006-03-07 2008-12-03 AstraZeneca AB Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them.
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
US20160208011A1 (en) * 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
UA109290C2 (en) * 2010-10-07 2015-08-10 Common Crystals and Salts of CCR3 Inhibitors
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
SG11201909207VA (en) * 2017-04-05 2019-11-28 Alkahest Inc Methods and compositions for treating retina-associated disease using ccr3-inhibitors
KR20190131078A (en) * 2017-04-05 2019-11-25 알카헤스트 인코포레이티드 Methods and compositions for treating aging-related disorders with CCR3-inhibitors

Also Published As

Publication number Publication date
CN112789044A (en) 2021-05-11
CL2021000724A1 (en) 2021-10-15
EP3856195A1 (en) 2021-08-04
MA53743A (en) 2022-01-05
WO2020069008A1 (en) 2020-04-02
CO2021003713A2 (en) 2021-04-08
BR112021004938A2 (en) 2021-06-01
EP3856195A4 (en) 2022-06-22
KR20210065950A (en) 2021-06-04
AU2019346456A1 (en) 2021-04-15
IL281578A (en) 2021-05-31
EA202190463A1 (en) 2021-06-29
JP2022502441A (en) 2022-01-11
MX2021002967A (en) 2021-08-11
CA3111433A1 (en) 2020-04-02
TW202027752A (en) 2020-08-01

Similar Documents

Publication Publication Date Title
IL269787B (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
HK1248153A1 (en) Methods and compositions for treating aging-associated impairments
IL277079A (en) Cartyrin compositions and methods for use
IL280134A (en) Anti-cd112r compositions and methods
IL278004A (en) Methods and compositions for treating aging-associated conditions
IL285496A (en) Methods for treating cholestasis
IL290840A (en) Compositions and methods for cd123 modification
ZA202101362B (en) Compositions and methods for treating the eye
GB201905559D0 (en) Composition and method
ZA202101342B (en) Compositions and methods for treating the eye
IL285886A (en) Compositions and methods for treating laminopathies
SG11202003261PA (en) Sanitizing compositions and methods for making and using same
SG11202104448WA (en) Compositions and methods
SG11202012055PA (en) Methods and compositions for preventing or treating calciphylaxis
GB201909542D0 (en) Composition and method
IL288440A (en) Compositions and methods for treating retinopathy
GB201817444D0 (en) Methods and compositions
ZA202101361B (en) Compositions and methods for treating the eye
ZA202101360B (en) Compositions and methods for treating the eye
ZA202007183B (en) Compositions and methods for treating the eye
GB201819987D0 (en) Methods and compositions
IL285796A (en) Methods and compositions for treating
IL290325A (en) Biopharmacuetical compositions and related methods
IL277463A (en) Compositions and methods for treating pruritus
IL281578A (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors